- ►diabetesjournals.org T Damci, S Yalin, H Balci, Z Osar, U Korugan, M … - Diabetes Care, 2004 - Am Diabetes Assoc OBJECTIVE—Orlistat leads to improved glycemic control in obese type 2 diabetic patients, which is
attributed to decreased insulin resistance associated with weight loss. Glucagon-like peptide 1
(GLP-1) and glucose-dependent ... Cited by 37 - Related articles - BL Direct - All 11 versions
- ►diabetesjournals.org [PDF] M Horowitz, C Feinle-Bisset, K Jones, M Nauck - Diabetes care, 2004 - Am Diabetes Assoc Several clinical trials (1) have demon- strated that vitamin E does not re- duce future major
cardiovascular (CV) events. However, these trials could not rule out the potential benefit for high-
risk subgroups. Diabetic ... Cited by 5 - Related articles - BL Direct - All 6 versions
- ►endojournals.org A Pilichiewicz, D O'Donovan, C Feinle, Y Lei, … - Journal of Clinical …, 2003 - Endocrine Soc This study examined the effects of the lipase inhibitor, orlistat, on gastric emptying of, and the
glycemic and incretin hormone responses to, a drink containing oil and glucose components in
patients with type 2 diabetes. ... Cited by 32 - Related articles - BL Direct - All 7 versions
DO'Donovan, M Horowitz, A Russo, C Feinle-Bisset, N … - Diabetologia, 2004 - Springer Aims/hypotheses. We examined the effects of lipase inhibition with orlistat on (i) gastric emptying
of, and (ii) the glycaemic, glucagon-like peptide-1 (GLP-1) and cardiovascular responses to, a
high-fat/carbohy- drate meal in ... Cited by 22 - Related articles - All 4 versions
[CITATION] Orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes …
CJ Hsieh, PW Wang, RT Liu, SC Tung, WY Chien, … - Diabetes research and …, 2005 - Elsevier Orlistat lowers lipids and improves insulin sensitivity, but its effect on other metabolic syndrome
related parameters is not known. To assess its influence on adiponectin, high sensitive C-reactive
protein (hs-CRP) and other ... Cited by 37 - Related articles - All 7 versions
PM Suter, G Marmier, C Veya-Linder, E Hänseler, J … - Atherosclerosis, 2005 - Elsevier Evidence suggests that metabolic phenomena during postprandial lipemia may be important in the
pathogenesis of atherosclerosis. Both lipid concentrations and lipoprotein subclass patterns may be
important cardiovascular risk ... Cited by 18 - Related articles - All 7 versions
- ►adelaide.edu.au [PDF] D O'Donovan, C Feinle-Bisset, J Wishart, … - British Journal of …, 2007 - Cambridge Univ Press The lipase inhibitor, orlistat, is used in the treatment of obesity and reduces fat absorption by
about 30 %. However, the mean weight loss induced by orlistat is less than expected for the degree
of fat malabsorption. It was ... Cited by 19 - Related articles - BL Direct - All 5 versions
KCB Tan, AWK Tso, SCF Tam, RWC Pang, KSL … - Diabetic Medicine, 2002 - pt.wkhealth.com Methods: The acute effect of a single dose of 120 mg orlistat on post-prandial glucose, lipids,
remnant lipoproteins and free fatty acids (FFA) was evaluated in a randomized, double-blind,
placebo-controlled cross-over study ... Cited by 24 - Related articles - BL Direct - All 6 versions
JH Goedecke, M Barsdorf, C Beglinger, NS Levitt, … - International Journal of …, 2003 - nature.com International Journal of Obesity is a monthly, multi-disciplinary forum for papers describing basic,
clinical and applied studies in biochemistry, genetics and nutrition, together with molecular, metabolic,
psychological and epidemiological aspects of obesity and related disorders.
Cited by 13 - Related articles - BL Direct - All 3 versions
